DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects

Information source: National Taiwan University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Subjects

Intervention: Gemfibrozil & red yeast rice (LipoCol) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: National Taiwan University Hospital

Official(s) and/or principal investigator(s):
Jyh-Chin Yang, M.D. Ph.D., Principal Investigator, Affiliation: National Taiwan University Hospital

Summary

Red yeast rice capsule (LipoCol Forte)is a nature product that has been demonstrated a significant cholesterol lowering effect which might be caused by addictive and/or synergistic effects of lovastatin (monacolin K) with other monacolins and substances in capsules. The usual dose of red yeast rice capsule(LipoCol Forte)for hypercholesterolemia is one capsule twice/day. Gemfibrozil is a fibric acid derivative (fibrate). It can reduce the levels of triglycerides and increase the levels of high-density lipoprotein cholesterol (HDL-C). Patients with mixed lipid disorders may therefore benefit from a combination of a statin and a fibrate. Although the combination of a fibrate and a statin is highly effective,concerns about an increased incidence of myopathy and even rhabdomyolysis have limited the widespread use of such combinations. Such combination therapies are prone to drug-drug interactions, which can lead to altered pharmacokinetic profiles of either drug, an effect observed for many statins in combination with fibrates. However, the drug-drug interactions have not been reported between red yeast rice capsule and gemfibrozil. The objective of the study is to evaluate the effect of gemfibrozil on the plasma concentrations of lovastatin and its active form, lovastatin acid, from red yeast rice capsule in healthy volunteers. In addition, the investigators also measure the plasma concentration of creatine kinase (CK) and co-enzyme Q10 for safety assessment.

Clinical Details

Official title: Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Evaluation of the pharmacokinetic parameters of lovastatin and lovastatin acid in healthy subjects

Secondary outcome: Evaluation of the plasma concentration of creatine kinase (CK) and co-enzyme Q10 in healthy subjects

Detailed description: A randomized,crossover study design with 2 periods was used. The washout time between the periods was 4 days. In first period, 600 mg red yeast rice capsule (LipoCol) was administered orally with 240 mL water at 8 AM. In second period, subjects took 600 mg gemfibrozil (two Lopid 300-mg capsule) at 7 AM and 7 PM for 2 days. On day 3, subjects took 600 mg gemfibrozil at 7 AM then 600 mg red yeast rice capsule was administered orally with 240 mL water at 8 AM. The volunteers had fasted overnight, a breakfast and dinner was severed 0. 5 hour after the administration of gemfibrozil. In addition, a high fat breakfast was served 0. 5 hour before and standard meal was served 4 and 10 hours after the administration of red yeast rice (LipoCol). The blood samples will be drawn prior to the dosing, and 0. 5, 1, 1. 5, 2, 2. 5, 3, 4, 6, 8 and 12 hours after the administration of red yeast rice(LipoCol)for detecting the plasma concentration of lovastatin and lovastatin acid. In addition, the blood samples will be drawn prior to the dosing, and 1, 2, 4, 6 and 12 hours after the administration of red yeast rice (LipoCol) for detecting the plasma concentration of creatine kinase (CK) and co-enzyme Q10.

Eligibility

Minimum age: 20 Years. Maximum age: 40 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Subjects must be at the age of 20-40 years old and be able to sign informed consent prior to study.

2. Body weight must be above 45 kilograms (kg) and within - 20 to +20% of ideal body

weight. 3. No clinically significant abnormalities were judged by the principal investigator based on the medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations. Exclusion Criteria: 1. Use of any prescription medication, over-the-counter medications or vitamins within 14 days prior to dosing. 2. Participation in any clinical investigation within 2 months prior to dosing or longer as required by local regulation. 3. Donation or loss of more than 500 milliliter (mL) blood within 3 months prior to dosing. 4. Presence of liver disease (Glutamic Oxaloacetic Transaminase (GOT), Glutamic Pyruvic Transaminase (GPT) or Total-bilirubin greater than 2-fold normal values) or renal disease (blood urea nitrogen (BUN) or creatinine greater than 1. 5-fold normal values). 5. Creatine kinase (CK) value greater than 1. 5-fold normal value. 6. A known hypersensitivity to statins and fibrates or their analogs. 7. Permanent confinement to an institution. 8. Individuals are judged by the investigator or co-investigator to be undesirable as subjects for other reasons.

Locations and Contacts

National Taiwan University Hospital, Taipei, Taiwan
Additional Information

Starting date: July 2011
Last updated: October 13, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017